These are good news. However, we should not put too much into it as is a VERY long shot.
The advantage of the test is that the CTC will be monitored, quantified and critical data will be gathered.
Now, lets asume that CTC progression "suddenly" goes to a halt. Well, as NP said, this will be a different company (and several people will be very rich).
However, most probable scenario CTC count is affected somewhat (reduction in progression, reduction on acceleration), the question is how much ? for how long? how significant ? adverse effects ? and so on and so on.
Regardless of what, first of all, lets hope it works for the patient and her family; it would be GREAT if her survival is significantly extended or illness stopped, or quality of life improved.
The stakes are high (in regards to the science) but, for CYDY, is a very long shot and a very long road ahead … However, is worth taking it for the thousands of patients with TNBC with little hope.
Lets keep our fingers crossed …